Francis P. Worden, MD

Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from other clinical trials.

Francis P. Worden, MD, discusses a real-world study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer.

Francis P. Worden, MD, discusses the background of a study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, including in those with BRAF-mutated, wild-type and BRAF untested tumors.

Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid cancer space.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.

Francis P. Worden, MD, discusses the efficacy findings from the phase 3 COSMIC-311 study of cabozantinib in thyroid cancer.

Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.